1. Home
  2. Labeler Index
  3. Preferred Pharmaceuticals Inc.
  4. 68788-8623
  5. Product Images: Duloxetine

Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01
  2. Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02
  3. Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03
  4. Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04
  5. Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05
  6. fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06
  7. fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07
  8. Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08
  9. Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09
  10. Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10
  11. Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11
  12. Duloxetine Delayed-Release Cap USP 60mg - 69d6387b 794f 415d 8013 23cca0a6984f 15

Product Label Images

The following 12 images provide visual information about the product associated with Duloxetine NDC 68788-8623 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01

Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02

This text provides information about the proportion of patients experiencing a relapse in a study comparing placebo to duloxetine. It includes data on the time from randomization to relapse in days and mentions the use of the Kaplan-Meier estimator method.*

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03

This data provides information on the proportion of patients with relapse based on the treatment (Placebo and Duloxetine) and the time from randomization to relapse in days. The Kaplan-Meier estimator method was used to analyze the relapse rates.*

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04

Percentage of Patients Improved with different doses of Duloxetine (60 mg and 20 mg) and Placebo are compared in terms of pain reduction from baseline. This data can help in assessing the efficacy of Duloxetine in managing pain symptoms.*

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05

fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06

fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06

This text provides information about the percentage of patients improved and the percent improvement in pain from baseline when given different doses of Duloxetine or a placebo. The data includes values for various levels of improvement.*

fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07

fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07

Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08

Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08

This is a description of the percentage of pediatric patients (aged 13 to 17) with Juvenile Fibromyalgia Syndrome achieving different levels of pain relief at week 12 in a study (FM-4). The graph compares the percentage of patients receiving Duloxetine 60mg once daily versus a placebo. Pain relief was measured using the Brief Pain Inventory - Modified short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30 mg once daily for 1 week and then increased to 60 mg once daily for 12 weeks. The results on the graph show the percent improvement in pain from baseline.*

Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09

Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09

The text provides data on the percentage of patients improved in a clinical trial comparing a placebo to duloxetine 60/120 mg taken once daily. The chart shows the percent improvement in pain from baseline.*

Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10

Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10

This is about the percentage of patients improved with Duloxetine 60 mg compared to a placebo for pain relief. It shows a chart with percentage improvements in pain from baseline for various time intervals.*

Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11

Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11

This is data related to the percentage of patients improved after treatment with a placebo and Duloxetine 60/120 mg once daily. The chart shows the percentage improvement in pain from the baseline. The data indicates 100% improvement for Duloxetine 60/120 mg, with a comparison to the placebo. The chart ranges from 10% improvement to 90%.*

Duloxetine Delayed-Release Cap USP 60mg - 69d6387b 794f 415d 8013 23cca0a6984f 15

Duloxetine Delayed-Release Cap USP 60mg - 69d6387b 794f 415d 8013 23cca0a6984f 15

This is a description of Duloxetine 60mg Delayed-Release Capsules, a generic version of Cymbalta. Each capsule contains 67.3mg of duloxetine hydrochloride. The capsules are blue and green, imprinted with LU Q03. The product is manufactured by Lupin Limited and is for prescription use only. The text also includes cautionary information about federal law prohibiting the transfer of the medication to anyone other than the prescribed patient. The information is available in both English and Spanish.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.